AIHealthcare Analytics

Overview

OpenEvidence is a medical AI platform designed to surface clinical evidence for physicians at the point of care. It has emerged as one of the most widely adopted AI tools among clinicians, distinguished by its focus on peer-reviewed evidence retrieval and synthesis rather than general-purpose conversational AI.

Stanford-Harvard NOHARM Study (2025–2026)

An independent benchmark study conducted by researchers at Stanford University School of Medicine and Harvard Medical School, known as NOHARM (Numerous Options Harm Assessment for Risk in Medicine), ranked 24 AI systems by clinical safety. Originally posted to arXiv in December 2025, the study found that four medical-specialized tools — including OpenEvidence — topped the rankings in a statistical tie. A separate finding from the same research ecosystem reported that physicians chose OpenEvidence over every other AI chatbot combined, underscoring strong clinician preference in head-to-head comparisons.

Funding and Valuation (2026)

As of July 2026, OpenEvidence was reported to be weighing a $200 million funding round at a $20 billion valuation, according to The Information (reported July 17, 2026). However, sources involved in the discussions indicated the deal was unlikely to proceed, citing concerns that it would dilute shares held by founders and existing investors. The same source noted that OpenEvidence had held acquisition talks with undisclosed parties, signaling significant strategic interest in the company.

Competitive Position

OpenEvidence's dominance in physician preference surveys and its top-tier safety ranking position it as the leading specialized clinical AI platform. Its valuation trajectory reflects broader investor enthusiasm for clinical-grade AI, even as the company navigates complex decisions about whether to raise capital, pursue acquisition, or remain independent.